CSL Behring Submits C1-INH For Hereditary Angioedema
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
C1-esterase inhibitor joins Jerini's Firazyr and Lev's Cinryze in race to gain orphan exclusivity for acute HAE, and block other entrants